1. Multidisciplinary care program in pre-end-stage kidney disease from 2010 to 2018 in Taiwan
- Author
-
Ming-Yen Lin, Min-Yu Chang, Pei-Yu Wu, Ping-Hsun Wu, Ming-Huang Lin, Chih-Cheng Hsu, Jer-Ming Chang, Shang-Jyh Hwang, and Yi-Wen Chiu
- Subjects
Male ,National Health Programs ,Renal Dialysis ,Taiwan ,Humans ,Kidney Failure, Chronic ,Female ,General Medicine ,Reimbursement, Incentive ,Aged - Abstract
The Taiwanese government launched a universal pay-for-performance (P4P) program in 2006 to promote multidisciplinary care for patients with stage 3b-5 chronic kidney disease (CKD). This study aimed to understand the enrollments, care processes, and outcomes of the P4P program between 2010 and 2018.We conducted a population-based study using the Taiwan National Health Insurance Research Data. We divided the incident dialysis population into joining and not joining P4P groups based on whether patients had joined the pre-ESRD program before dialysis or not. Trends in the medications prescribed, anemia correction, vascular access preparation before dialysis initiation, and cumulative survival rate were compared.The program included more than 100,000 patients with late-stage CKD. Enrollment increased by almost 100% from 2010 to 2018, with increases seen in those over 75 years old (127.5%), male (96.7%), and earlier CKD stages (≥35% stage 3b in 2018). Females were more likely to stay being enrolled. The joining P4P group was prescribed more appropriate medications, such as erythropoietin-stimulating agents and statins. However, a high number of patients were still prescribed metformin (≥40%) and non-steroidal anti-inflammatory drugs (≥20%). Compared to the not joining P4P group, the patients in the P4P group had better anemia management, dialysis preparation, and post-dialysis survival.The patients in the joining P4P program group were delivered more appropriate CKD care and were associated with better survival outcomes. Polices and action plans are needed to extend the coverage of and enrollment in the P4P program.
- Published
- 2022